Abstract
Synthesis of intrinsically radiolabeled nanoparticles is an emerging concept in cancer theranostics and is expected to play an imperative role in translating nanotechnology research into the nuclear medicine industry. In order to reduce reliance on cyclotron produced 64Cu (t1/2 = 12.7 h, EC 45%, β+ 17.9%, β– 37.1%) and increase global accessibility of this radioisotope for preclinical and clinical investigations, we have explored the feasibility of using neutron-activated 64Cu produced in research reactors for potential use in cancer theranostics. A viable strategy has been developed for production of 64Cu in medium-flux research reactors and its utilization toward industrial-scale (GBq level) synthesis of intrinsically radiolabeled 64CuS nanoparticles (∼30 nm particle size). The synthesis procedure was easily executable in a hot cell equipped with remotely operable gadgets and 64CuS nanoparticles could be synthesized in a form suitable for clinical administration. The stability of the nanoparticles under...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
